OncoFocus52 Every variant class, one small sample.
A targeted NGS assay that profiles 52 solid-tumour genes for hotspot SNVs, indels, copy-number gains and gene fusions from DNA and RNA in a single workflow — from as little as 10 ng of each, including FFPE fine-needle aspirates and core-needle biopsies. Built on the Oncomine Focus Assay (Thermo Fisher Scientific) and run on the Ion GeneStudio S5.
OncoFocus52 at Nucleome Informatics
OncoFocus52 reads 52 genes that drive solid tumours or are targeted by on-market oncology drugs and published evidence, with content driven by the Oncomine Knowledgebase. DNA and RNA are analysed together, so one small biopsy answers questions that would otherwise need several separate tests.
Who should order this test
- Oncologists and pathologists who need broad solid-tumour biomarker profiling from limited samples — FFPE blocks, fine-needle aspirates and core-needle biopsies
- Cancer researchers and translational programmes that need sequence variants, copy-number gains and fusions from one assay
- Clinical research teams where sample conservation matters as much as breadth
What you receive
- Variant calls for all four classes: SNVs, indels, copy-number gains and gene fusions
- Evidence-linked annotation of each variant to drug labels and published evidence (Oncomine Reporter)
- A structured report with coverage, QC metrics and per-variant evidence
- Raw data and variant-call files for your records
- A review call with our scientific team to discuss the findings in context
Why one assay for all variant classes?
- Sample conservation: DNA and RNA from the same specimen are analysed in one workflow — no repeat extraction or re-biopsy for each biomarker.
- Fusions included: RNA-based detection covers ALK, ROS1, RET and NTRK1/2/3 fusions, which DNA-only hotspot panels can miss.
- Copy-number gains: amplifications of genes such as ERBB2, MET, EGFR and FGFR1 are called from the same DNA library.
- Speed: a 3-day tissue-to-report platform workflow on Ion Torrent sequencing, with optional Ion Chef automation.
52 genes, grouped by variant class
Content of the Oncomine Focus Assay as published by Thermo Fisher Scientific. Some genes appear in more than one group; there are 52 unique genes in total.
Hotspot genes SNVs and indels · 35 genes · DNA
Copy-number genes amplifications · 20 genes · DNA
Fusion genes RNA · 23 genes
The DNA panel uses 269 amplicons; the RNA panel targets 271 known fusion isoforms plus expression-control amplicons. Copy-number analysis is designed for gains (amplifications) of these oncogenes, not for gene deletions.
What to send, what you receive
Reference inputs from the assay user guide. Final requirements are confirmed at intake.
| Sample type | What to send | Notes |
|---|---|---|
| FFPE tissue | FFPE block, or unstained sections/scrolls with a matching H&E slide | Pathologist-marked tumour area preferred; ship at room temperature |
| Fine-needle aspirate / core-needle biopsy | FFPE cell block or core | Validated for low-volume biopsies |
| Fresh-frozen tissue | Frozen tissue | Ship on dry ice; avoid freeze–thaw |
| Extracted nucleic acids | 10 ng DNA and 10 ng DNase-treated RNA per reaction | Quantified by Qubit or TaqMan RNase P (DNA) and Qubit RNA HS (RNA); spectrophotometry is not recommended |
Tumour content matters: variants are reported down to about 5% allele frequency, so low-tumour samples reduce sensitivity. RNA quality drives fusion detection — send the freshest material available when fusions are the priority.
Deliverables
- Report of detected SNVs, indels, copy-number gains and fusions, with evidence-linked annotation (Oncomine Reporter)
- Coverage and QC metrics per sample, including RNA expression controls and no-template controls
- Raw data and variant-call files (BAM, VCF and fusion tables)
- A review call with our scientific team
From tissue to report
The documented platform workflow takes about 3 days from extracted sample to report. Overall turnaround, including shipping and review, is agreed per project.
Documented sensitivity and specificity
Thermo Fisher's analytical performance summary for the Oncomine Focus Assay, using clinical research samples sequenced on the Ion GeneStudio S5 System.
| Variant class | Sensitivity | PPV (positive predictive value) | Reproducibility |
|---|---|---|---|
| SNVs | 98.77% | 99.63% | 99.6% |
| Indels | 100% | 100% | 100% |
| CNVs (gains) | 96.42% | 100% | 96.42% |
| Gene fusions | 100% | 100% | 100% |
| Overall | 98.70% | 99.67% | 99.01% |
Source: Thermo Fisher Scientific, Oncomine Focus Assay analytical performance summary. Default reporting thresholds in the Ion Reporter workflow: hotspot variants at allele frequency ≥5% with ≥10 supporting reads; copy-number gains where the lower 5% confidence bound of fold change is ≥2.
From first principles to study design
New here? Start with Foundations. Planning a study or reading a report? Jump to Practitioner or Expert.
Six ideas that explain what this test is and why it matters.
What is a targeted NGS panel?
Instead of sequencing the whole genome, a panel reads a selected set of genes deeply and affordably — here, 52 genes that drive solid tumours or predict therapy response.
SNVs, indels, CNVs and fusions
SNVs are single-letter changes; indels are small insertions or deletions; CNVs here are gene amplifications; fusions are two genes joined by a chromosome rearrangement.
Why DNA and RNA?
DNA shows sequence changes and copy number; RNA shows fusions directly as fused transcripts. Using both from one sample gives the full picture.
What is FFPE?
Formalin-fixed, paraffin-embedded tissue is how pathology labs store biopsies. Fixation damages DNA and RNA, so this short-amplicon chemistry is built for degraded material.
What will I get?
A report of detected variants linked to therapies and evidence, with coverage and QC metrics, the raw data, and a review call with our team.
Who is this test for?
Oncologists, pathologists and cancer researchers who need broad biomarker profiling from small or archived samples.
How each step works and what to check in the report.
Library preparation
10 ng DNA is amplified directly; 10 ng RNA is first reverse-transcribed to cDNA. Amplification cycles are increased for FFPE material to compensate for damage.
Templating and sequencing
Barcoded libraries are pooled, templated on the Ion Chef and sequenced on an Ion 520 chip on the Ion GeneStudio S5.
Variant calling
Torrent Suite runs QC and alignment; Ion Reporter calls hotspot SNVs/indels, copy-number gains and fusions from the DNA and RNA data.
Evidence-linked reporting
Oncomine Reporter links each biomarker to drug labels, guidelines and published evidence, and our team reviews the findings with you.
Quality metrics you will see
Mapped reads, amplicon coverage and uniformity, RNA expression-control reads, fusion-supporting read counts, and clean no-template controls.
Samples in practice
FFPE blocks or sections, FNA cell blocks and core biopsies all work; tumour-rich areas marked on an H&E slide give the best sensitivity.
The decisions that determine how to read a positive — or a negative — result.
Performance by variant class
Overall sensitivity is 98.70% and PPV 99.67%; CNV sensitivity (96.42%) is the lowest class, so treat a CNV-negative result with the most caution.
Tumour content and the 5% threshold
Heterozygous variants in a sample with 10% tumour cells appear at about 5% allele frequency — the reporting floor. Enrich tumour area before extraction where possible.
Fusions depend on RNA
The RNA panel detects 271 known fusion isoforms. Novel partners or breakpoints outside the design are not detected, and badly degraded RNA lowers sensitivity.
Copy-number scope
CNV calling targets amplifications of 20 oncogenes. Deletions of tumour suppressors (e.g. CDKN2A, PTEN) are outside the assay design.
Panel vs broad profiling
OncoFocus52 trades breadth for speed, depth and sample economy. For TMB, MSI, tumour suppressors or discovery, choose OncoTotal500 or genome-wide approaches.
Clinical validation
Thermo Fisher labels the Oncomine Focus Assay kit For Research Use Only. Nucleome has validated OncoFocus52 in its own laboratory for clinical use.
- AmpliSeq
- amplicon-based targeted enrichment chemistry suited to low-input, degraded samples.
- FFPE
- formalin-fixed paraffin-embedded tissue; standard pathology storage.
- FNA
- fine-needle aspirate; a minimally invasive biopsy.
- Allele frequency
- the percentage of reads carrying a variant; diluted by normal cells in the sample.
- Ion Chef
- automated instrument for library templating and chip loading.
- PPV
- positive predictive value; the share of reported calls that are true.
Built for small, difficult samples
The platform, chemistry and software behind the test.
Ion AmpliSeq chemistry
Short amplicons give robust results from low-input and FFPE-damaged DNA and RNA.
52-gene multi-class content
Hotspot, copy-number and fusion groups spanning EGFR, KRAS, BRAF, ERBB2, MET, ALK, ROS1, RET and NTRK1/2/3.
Ion GeneStudio S5
Semiconductor sequencing; the S5 chip range spans 2M–130M reads per run, and an Ion 520 chip handles up to seven paired DNA/RNA samples.
Ion Chef automation
Hands-free templating and chip loading for reproducible, low-touch processing.
Integrated informatics
Torrent Suite for run QC, Ion Reporter for variant and fusion calling, Oncomine Reporter for evidence-linked reports.
Connected to our bioinformatics
Further interpretation, tiering and multi-omics context through our Bioinformatics team.
What this test does and does not cover
Service highlights
What you can expect from our team in Hyderabad.
All four classes, one run
SNVs, indels, copy-number gains and fusions from DNA and RNA — no repeat testing.
10 ng input, FFPE-ready
Works from fine-needle aspirates, core biopsies and archived blocks.
Evidence-linked reports
Each biomarker linked to drug labels and published evidence.
Documented performance
98.70% sensitivity and 99.67% PPV overall in Thermo Fisher's analytical summary.
Fast by design
A 3-day platform workflow with optional Ion Chef automation.
A path to broader testing
Step up to OncoTotal500 or genome-wide sequencing when the question needs more breadth.
Frequently asked, in plain language
From the basics to the finer points of interpretation.
basicWhat is OncoFocus52?
basicWhat samples does it accept?
basicWhich genes are covered?
intermediateWhy does the assay use both DNA and RNA?
intermediateWhat will the report contain?
intermediateIs OncoFocus52 validated for clinical use?
intermediateDoes it detect gene deletions?
advancedHow sensitive is the assay?
advancedCan it detect NTRK fusions?
advancedHow does it compare with broader profiling?
advancedHow many samples run together?
Key literature & resources
Assay content, workflow and performance are documented by Thermo Fisher Scientific.
- Thermo Fisher Scientific. Oncomine Focus Assay — product information, gene list, workflow and analytical performance summary. thermofisher.com
- Thermo Fisher Scientific. Oncomine Focus Assay User Guide (Pub. No. MAN0015819, Rev. D.0, 18 September 2023; Cat. Nos. A29230, A35957, A42008). PDF
- Thermo Fisher Scientific. Ion GeneStudio S5 Series, Ion Chef System, Torrent Suite, Ion Reporter and Oncomine Reporter product documentation.









